

Introducing Libifem®

Fenugreek, or Trigonella foenum-graecum is amongst the oldest known medicinal plants with written documentation citing its benefits as far back as 1500 B.C. With the assistance of modern manufacturing methods, Gencor has developed a novel fenugreek seed extract for women - Libifem®. The modern extract features a standardization to a proprietary matrix of saponin glycosides known as FenusideTM. Through years of rigorous scientific research, a whole host of benefits have been elucidated including supporting sexual health, menopausal health, as well as improving lean mass and lower-body strength while simultaneously reducing fat mass. * All of these benefits can be achieved with a low dosage of just 600 milligrams (mg) per day.

The aforementioned health benefit categories continue to be a major area of focus for women:

Sexual Health:

In the United States, it has been estimated that almost 27% of premenopausal women, and 52.4% of naturally postmenopausal women struggle with reduced sexual desire.

Menopausal Health

An estimated 1 million women go through menopause each year in the U.S. alone.

· Lean Mass, Strength, & Fat Mass

Research on ingredients for enhancing athletic performance have historically underrepresented women. One audit reported that there was 8-times less studies using performance-based supplement that were exclusively conducted in women as compared to those exclusively conducted on men.

Key Benefits (600mg/day)

Sexual Health Support*

- Helps to to support sexual activity, as well as sexual cognition, arousal, sexual behavior, orgasm, and drive in premenopausal women.
- Menopausal Health Support*
 - Helps to reduce hot flashes and night sweats as well as improve menopause related quality of life and more specifically vasomotor, psychosocial, physical, and sexual domains in menopausal women.
- Lean Mass and Lower-Body Strength Improvement, Fat Mass Reduction*
 - Helps to improve total lean mass as well as total lean mass in the legs in premenopausal women.
 - Helps to reduce total fat mass as well as trunk fat mass in premenopausal women.

Libifem® Formulation Features


- Self affirmed GRAS
- Allergen free (Major 9)
- Vegan / vegetarian
- Kosher & Halal
- Suitable for capsules, tablets, softgels, and powders

Science inside

Source: Steels E., Steele, M.L., Harold, M., Coulson, (2017). Phytotherapy Research. 31(9), 1316-1322

- Study Design: Randomized, double-blind, placebo-controlled trial
- Subjects: 115 women aged 45 to 65 years of age
- Intervention: 300mg Libifem® twice daily (600mg/day) or a matching placebo
- Study Duration: 12 weeks

MENQOL Libifem® vs. Placebo



Hot Flushes & Night Sweats (Total number over a 7-day period) 50 40 30 Libifem®

Week 8

Week 12

Key Results

- Significant reduction in MENQOL study results in comparison to placebo.
 - Indicates that Libifem® supports all MENQOL sub-domains (vasometer, psychosocial, physical).
- Significant improvement in menopausal symptoms, such as hot flushes and night sweats in comparison to placebo.

Baseline


Week 4

Indicates that Libifem® supports menopausal symtom relief.

Science inside

Source: Rao A., Steels E., Beccaria G., Inder W., Vitetta L., (2015). Phytotherapy Reseearch. 31(9), 1316-1322

- Study Design: Randomized, double-blind, placebo-controlled trial
- **Subjects**: 80 women aged 20 to 49 years of age
- Intervention: 600mg Libifem® once daily (600mg/day) or a matching placebo
- Study Duration: 8 weeks




Key Results


- Significant increase in estradiol and free testosterone within normal female physiological limits in comparison to placebo.
 - Indicates that Libifem® supports an increase in estradiol within a healthy range.
- Significant improvement in the total score and in all five domains of the DISF-SR.
 - Indicates that Libifem® supports an sexual cognition, arousal, experience, climax, and relationship.


Science inside

Source: Rao A., Calyton P., (2023). Frontiers in Sports and Active. 5.

- Study Design: Randomized, double-blind, two-active, placebo-controlled trial
- **Subjects**: 129 women aged 25 to 45 years of age
- Intervention: 300mg Libifem® once daily (300mg/day) or 600mg once daily (600mg/day) or a matching placebo
- Study Duration: 8 weeks







Key Results

- Significant increase in muscle strength, power and endurance in comparison to placebo.
 - Indicates that Libifem® supports improved athletic performance.
- Significant improvement in aerobic capacity in comparison to placebo.
 - Indicates that Libifem® supports improvement for endurance athletes.
- Significant improvement in body composition in comparison to placebo.
 - Indicates that Libifem® supports increased metabolism and sports performance.
- 1. Fenugreek: Biology and Applications. (2021). Singapore: Springer Nature Singapore.
- 2. Rao, A., Steels, E., Beccaria, G., Inder, W. J., & Vitetta, L. (2015). Influence of a specialized Trigonella foenum-graecum seed extract (libifem), on testosterone, estradiol and sexual function in healthy menstruating women, a randomised placebo controlled study. Phytotherapy Research, 29(8), 1123-1130.
- 3. Steels, E., Steele, M. L., Harold, M., & Coulson, S. (2017). Efficacy of a proprietary Trigonella foenum-graecum L. de-husked seed extract in reducing menopausal symptoms in otherwise healthy women: a double-blind, randomized, placebo-controlled study. Phytotherapy Research, 31(9), 1316-1322
- 4. Briskey, D., Clayton, P., & Rao, A. Libifem®(Trigonella foenum-graecum) in conjunction with exercise on muscle strength, power, endurance, and body composition in females aged between 25 and 45 years. Frontiers in Sports and Active Living, 5, 1207013.
- 5. West, S. L., D'Aloisio, A. A., Agans, R. P., Kalsbeek, W. D., Borisov, N. N., & Thorp, J. M. (2008). Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Archives of internal medicine, 168(13), 1441-1449.
- 6. https://www.naturalproductsinsider.com/business-operations/females-are-under-represented-both-subjects-and-leaders-health-research





Version 10152023